Related Experiment Video

Updated: Apr 24, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

7.2K

Recent advances and future directions in the management of hepatitis C infections

Victoria Belousova1, Ahmed A Abd-Rabou2, Shaker A Mousa1

  • 1The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, One Discovery Drive, Rensselaer, NY 12144, USA.

Pharmacology & Therapeutics
|September 10, 2014
PubMed

Insights

Hepatitis C virus (HCV) infection is a growing US health crisis. New treatments like sofosbuvir and simeprevir offer improved efficacy and safety, but cost remains a challenge for widespread hepatitis C treatment.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis C virus (HCV) infection is a significant cause of mortality in the US, with increasing incidence.
  • Treatment challenges include host, viral, and drug-related factors, necessitating novel therapeutic strategies.
  • Previous treatments like telaprevir and boceprevir showed improved efficacy but faced limitations due to resistance, side effects, and narrow activity spectrum.

Purpose of the Study:

  • To review the evolution of hepatitis C virus treatment strategies.
  • To highlight advancements in antiviral therapies and emerging treatment modalities.
  • To discuss the impact of new drugs on treatment outcomes and accessibility.

Main Methods:

  • Literature review of current and emerging hepatitis C virus therapies.
  • Analysis of treatment efficacy, resistance patterns, and safety profiles.
  • Examination of economic factors influencing treatment accessibility.

Main Results:

  • Telaprevir and boceprevir improved outcomes for genotype 1 HCV but had limitations.
  • Sofosbuvir and simeprevir, approved in late 2013, offer higher resistance barriers, better safety, and superior efficacy.
  • High costs of newer agents may impede widespread adoption and treatment access.

Conclusions:

  • Recent advancements in hepatitis C virus treatment have significantly improved patient outcomes.
  • Ongoing research into interferon-free regimens, vaccines, and nanotechnology promises further progress.
  • Addressing treatment cost is crucial for broader access to effective hepatitis C management.

Keywords:
HCV genotypesHepatitis C preventionHepatitis C treatmentHepatitis C virusInterferon-free regimensVaccine

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

23.7K
Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

5.5K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
74
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
17
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
54
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
872
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
649